Anal cancer is a relatively uncommon cancer that forms in the tissues of the anal canal, the short tube at the very end of the large intestine. The anal canal is only about 3 to 5 centimeters long, but several types of cells line it, and cancer can develop from any of them. The most common type by far is squamous cell carcinoma, which arises from the flat cells lining the inside of the canal. When caught early and still confined to its original site, anal cancer has an 85% five-year survival rate.
Types of Anal Cancer
Most anal cancers are squamous cell carcinomas, which develop from the skin-like cells that line the lower portion of the anal canal. Less commonly, adenocarcinoma can form from the glandular cells higher up in the canal, closer to the rectum. Other rare types include small cell carcinoma and undifferentiated carcinoma.
Cancer can also develop on the perianal skin, the area within about 5 centimeters of the anal opening. Perianal cancers include squamous cell carcinoma, basal cell carcinoma, and a rare condition called Paget’s disease. These are staged and treated somewhat differently from cancers inside the canal itself.
Common Symptoms
Anal cancer can develop without any noticeable symptoms at first. When signs do appear, bleeding from the anus or blood in the stool is the most common. Other symptoms include pain or pressure in the anal area, a lump or growth near the anus, persistent itching, and changes in bowel habits like narrower stools or new constipation. Some people feel a constant sensation of fullness or urgency, as though they need to have a bowel movement even after they just had one.
These symptoms overlap with hemorrhoids and other benign conditions, which is why anal cancer is sometimes dismissed or diagnosed late. Any rectal bleeding or persistent change that lasts more than a few weeks is worth getting checked.
The Role of HPV
Human papillomavirus, the same virus linked to cervical cancer, is the primary driver behind most anal squamous cell carcinomas. HPV infects the normal cells lining the anal canal and, over time, triggers a step-by-step transformation. Healthy tissue first develops low-grade precancerous changes, then high-grade changes, and eventually invasive cancer.
The virus does this through two proteins it produces after infecting a cell. One disables the cell’s main tumor-suppressing mechanism (p53), and the other blocks a second safeguard (Rb) that normally keeps cell growth in check. Together, these proteins also reactivate an enzyme that lets damaged cells keep dividing indefinitely rather than dying off as they normally would. This combination of unchecked growth and disabled safety systems is what makes HPV-driven anal cancer possible.
Other Risk Factors
Beyond HPV infection, a weakened immune system is the most significant risk factor. People living with HIV face substantially higher rates of anal precancer, and those who have progressed to an AIDS diagnosis have rates of precancerous anal changes nearly three times higher than HIV-positive individuals without AIDS. The connection is straightforward: a suppressed immune system is less capable of clearing HPV infections and controlling abnormal cell growth before it becomes cancer.
Organ transplant recipients and others on long-term immune-suppressing medications face a similar elevated risk. Smoking independently increases the likelihood of anal cancer, likely because tobacco chemicals damage DNA in the anal lining and weaken the local immune response. Having multiple sexual partners, a history of receptive anal intercourse, and a history of other HPV-related cancers (cervical, vulvar, vaginal) also raise risk.
How Anal Cancer Is Diagnosed
Diagnosis typically begins with a physical exam, including a digital rectal exam where a clinician feels for lumps or abnormalities. If something seems off, the next step is an anoscopy: a thin, flexible tube with a light and lens is inserted into the anal canal, giving a clear view of the lining. During this procedure, a small tissue sample (biopsy) can be collected through the anoscope and sent to a lab, where a pathologist examines the cells under a microscope to confirm whether cancer is present and what type it is.
If cancer is confirmed, imaging scans help determine whether it has spread beyond the anal canal. Staging follows the TNM system, which evaluates three things: the size of the tumor, whether nearby lymph nodes are involved, and whether cancer has reached distant organs like the liver or lungs. Tumors 2 centimeters or smaller are classified T1, those between 2 and 5 centimeters are T2, those larger than 5 centimeters are T3, and tumors of any size that have grown into neighboring organs like the bladder or vagina are T4.
Treatment
Unlike most other cancers of the lower digestive tract, anal cancer is primarily treated with a combination of radiation and chemotherapy rather than surgery. This approach, first developed in the 1970s and refined since, is remarkably effective at eliminating the tumor while preserving the anal sphincter and normal bowel function. The standard regimen combines radiation therapy with two chemotherapy drugs delivered simultaneously. Multiple large clinical trials have confirmed that this specific two-drug combination remains the most effective first-line treatment, outperforming alternatives tested against it.
Treatment typically spans five to six weeks. The radiation is targeted at the tumor and surrounding lymph nodes, while the chemotherapy drugs sensitize the cancer cells to radiation damage. Most patients complete the entire course as outpatients, though side effects like skin irritation, fatigue, and digestive discomfort in the treatment area are common during and immediately after the course.
Surgery is reserved for specific situations. Small, superficial cancers of the perianal skin can sometimes be removed with a local excision. For cancers that don’t respond to chemoradiation or that recur afterward, a more extensive operation called an abdominoperineal resection may be necessary. This procedure removes the anus, rectum, and part of the colon, requiring a permanent colostomy. It’s considered a last resort, used only when the standard approach fails.
Survival Rates by Stage
Prognosis depends heavily on how far the cancer has spread at the time of diagnosis. Based on data from 2016 through 2022, the five-year relative survival rates break down clearly by stage:
- Localized (cancer confined to the anal canal): 85.0%
- Regional (spread to nearby lymph nodes): 70.1%
- Distant (spread to organs like the liver or lungs): 36.5%
These numbers reflect averages across all patients and all treatment approaches. Individual outcomes vary based on tumor size, overall health, immune status, and how well the cancer responds to chemoradiation.
Prevention Through HPV Vaccination
Because HPV drives the majority of anal cancers, vaccination offers a powerful prevention tool. In a randomized, double-blind trial of sexually active men who have sex with men aged 16 to 26, the HPV vaccine reduced high-grade anal precancerous lesions related to the targeted HPV strains by about 75% among those who received all three doses before exposure to the virus. Even in the broader group that included people with possible prior exposure, the reduction was 54%.
The vaccine also helps after precancer has already been treated. A study of men over 18 with a history of treated high-grade anal precancer found that those who received the HPV vaccine afterward had roughly half the risk of recurrence compared to unvaccinated patients, a protective effect lasting at least three years. The HPV vaccine is currently recommended for everyone through age 26, with the option of vaccination up to age 45 after discussion with a healthcare provider. Vaccination works best before any HPV exposure, which is why routine immunization is recommended starting at age 11 or 12.